FDA, EMA to review PET imaging agent florbetaben

03/21/2013 | AuntMinnie.com (free registration)

Piramal Imaging has announced that the FDA and the European Medicines Agency have agreed to review its PET amyloid imaging agent florbetaben. The company submitted applications to the agencies for the use of the agent to image beta amyloid in adults who have cognitive impairment. A phase III study found the agent is useful in eliminating Alzheimer's disease as a cause of impairment.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Medical Director - Physician
Willamette Valley Community Health
Salem, OR